Probes For Detection Of Animal Nucleotide Sequences Patents (Class 536/24.31)
  • Patent number: 10378016
    Abstract: The invention provides aptamer-gene modulator conjugates, where the aptamer and the gene modulator are linked together. The invention further provides a method for cell-specific delivery of gene modulators to hard to transfect cells such as CD4+ cell.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: August 13, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Judy Lieberman, Lee Adam Wheeler
  • Patent number: 9752187
    Abstract: The present application describes methods for accurate and cost-effective categorization of DNA samples into different types of in vitro generated DNA or different types of natural DNA such as from different tissues and/or physiological/pathological states. The invention achieves categorization by comparing “signal ratios” that are correlated to ratios of methylation levels at specific genomic loci, but does not rely on calculation of actual methylation levels at any genomic locus. Therefore the disclosed inventive method eliminates the requirement for external DNA species and controls, thereby simplifying and increasing the accuracy of the assay. The described inventive technology also enables performing the categorization of DNA together with DNA profiling in the same reaction, thereby allowing for concomitant categorization and determination of identity of the samples.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: September 5, 2017
    Assignee: Nucleix
    Inventors: Adam Wasserstrom, Danny Frumkin
  • Patent number: 9730979
    Abstract: The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: August 15, 2017
    Assignee: COGNOSCI, INC.
    Inventors: Michael P. Vitek, Dale J. Christensen, Jessica Oddo
  • Patent number: 9173943
    Abstract: The present invention relates to imprinted polymer nanoparticles. In particular, the present invention provides imprinted polymer nanoparticles polymerized in the presence of a target molecule (e.g., peptide), wherein the imprinted polymer nanoparticles comprise vinyl, acryl, and/or methacryl monomers, wherein the monomers have affinity for the target molecule. The present invention also relates to methods of using imprinted polymer nanoparticles in biomacromolecular purification methods (e.g., to purify monoclonal antibodies or hormones), in toxin elimination methods (e.g., hemoperfusion), in diagnostics, in research, as well as in therapeutic methods (e.g., therapeutic methods where antisera or monoclonal antibodies are normally employed).
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Yu Hoshino, Kenneth J. Shea
  • Patent number: 9145561
    Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: September 29, 2015
    Assignee: Interexon Corporation
    Inventors: Zhixin Shi, Jack Q. Wilkinson, Donald S. Walters, C. Peter Romaine
  • Patent number: 9145449
    Abstract: The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or the antibody described herein to a subject in need thereof.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 29, 2015
    Assignee: CHANG GUNG MEMORIAL HOSPITAL, LINKOU BRANCH
    Inventors: Tzu-Hao Wang, Chia-Lung Tsai, Angel Chao
  • Patent number: 9140707
    Abstract: A method for generating antibodies preferable to either a normal protein and a mutated form of the normal protein, respectively, where a mutation associated with the mutated form includes either a single point mutation or a small number of point mutations where the method includes creating first and second antigenic peptides of a predetermined length corresponding respectively to common regions of the normal target protein and the mutated form, where the common regions are identical to one another except for the point mutation of the mutated form, obtaining first and second antibodies by multiplying the first and second antigenic peptides via hybridoma methods, and identifying the respective affinities of the first and second antibodies for the normal target protein and the mutated form. Also included are methods of using the first and second antibodies to detect and quantify respective amounts of a normal target protein and a mutated form of the target protein.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: September 22, 2015
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Kyung Aih Kang, Stephen Peiper
  • Patent number: 9063139
    Abstract: Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: June 23, 2015
    Assignees: The Trustees of Columbia University in the City of New York, University of Iowa Research Foundation, The United States of America, As Represented By the Secretary of the Department of Health and Human Services
    Inventors: Rando L. Allikmets, Gregory S. Hageman, Michael C. Dean, Albert M. Gold
  • Publication number: 20150141287
    Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventor: John B. Vincent
  • Publication number: 20150141391
    Abstract: The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 21, 2015
    Inventors: Arul M. Chinnaiyan, Dan Robinson, Yi-Mi Wu
  • Publication number: 20150141277
    Abstract: A method for the measurement of the amount or difference in the amounts of 2 or more nucleic acid targets in a sample, the method comprising the steps of attaching to nucleic acids present in the sample (1) a tag which allows the nucleic acids to be captured to a solid support; and (2) a labelled probe for a first nucleic acid target present in the sample and a labelled probe for second nucleic acid target present in the sample, and then measuring the amount of each labelled probe or difference in the amount of labelled probes; wherein the probe is not a single labelled nucleotide.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Edwin Southern, Dietrich Lueerssen, Oliver Miller, Natalie Milner
  • Patent number: 9034837
    Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: May 19, 2015
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
  • Patent number: 9035036
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: May 19, 2015
    Assignees: The General Hospital, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Publication number: 20150133333
    Abstract: Disclosed are kits and methods for diagnosing a person with, or assessing a person's risk for developing, sarcoidosis and/or complicated sarcoidosis.
    Type: Application
    Filed: September 11, 2014
    Publication date: May 14, 2015
    Inventors: Joe G.N. Garcia, Tong Zhou, Wei Zhang, Roberto Machado
  • Patent number: 9029084
    Abstract: A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: May 12, 2015
    Assignee: Qiagen Manchester Limited
    Inventors: David Mark Whitcombe, Nicola Jo Thelwell, Paul Francis Ravetto
  • Publication number: 20150126399
    Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Hila Benjamin
  • Publication number: 20150125868
    Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: VÉRONIQUE GELSI-BOYER, DANIEL BIRNBAUM
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150110733
    Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identif
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Amir TCHELET, Michael HAYDEN, Liat HAYARDENY, Colin James Douglas ROSS, Iris GROSSMAN, David LADKANI
  • Patent number: 9012619
    Abstract: Detection probes are provided that are capable of detecting a sequence to be detected containing a mutation even when a sequence not to be detected containing no mutation coexists with the sequence to be detected containing a mutation, which are different only in a single base from each other. At least one oligonucleotide selected from the group consisting of SEQ ID NOs: 2˜16 is used as a probe. Even in a sample containing an abl gene in which a mutation has occurred and an abl gene in which no mutation has occurred, the use of such probes in, for example, Tm analysis allows the mutation to be detected.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: April 21, 2015
    Assignee: Arkray, Inc.
    Inventors: Mitsuharu Hirai, Satoshi Majima, Taira Maekawa, Shinya Kimura
  • Patent number: 9006199
    Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: April 14, 2015
    Assignee: Silenseed Ltd.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
  • Publication number: 20150099747
    Abstract: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 9, 2015
    Inventors: Xiaoju Max Ma, Chitra Manohar, Alison Tsan
  • Patent number: 9000144
    Abstract: In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: April 7, 2015
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Thomas Tuschl, Mariana Lagos-Quintana, Winfried Lendeckel, Jutta Dammann, Reinhard Rauhut
  • Patent number: 8999648
    Abstract: A system (100) for classifying a biological test sample, including a database (112) populated with reference expression data. The reference expression data includes expression levels of a plurality of molecules (polynucleotides or polypeptides), including a set of marker molecules, in a plurality of reference samples. Each reference sample has a pre-assigned value for each of one or more clinically significant variables. The system includes at least one processor (110) and at least one storage medium containing program instructions for execution by said processor (110). The program instructions cause the processor to accept (122) input expression data including a test vector of expression levels of the marker molecules in the biological test sample; and pass the input expression data to one or more analysis programs (130a, 130b, 35).
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 7, 2015
    Assignee: Signal Genetics, Inc.
    Inventor: Ryan Van Laar
  • Patent number: 9000142
    Abstract: There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently bound to the antisense nucleobase polymer, wherein the photocleavable sense nucleobase polymer comprises a plurality of nucleobase polymers connected by a photocleavable linkage. There is also disclosed a method for controlling the time and spatial position of gene expression comprising selecting a target mRNA, introducing the photocleavable sense-antisense nucleobase polymer complex into a cell, and selectively irradiating the cell with light.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: April 7, 2015
    Assignee: Syntrix Biosystems, Inc.
    Inventor: John A. Zebala
  • Publication number: 20150094231
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 2, 2015
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20150088430
    Abstract: The invention in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 26, 2015
    Inventor: Duncan H. Whitney
  • Patent number: 8987222
    Abstract: The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly-sized patient populations. Silencing agents having enhanced discriminatory properties are also featured.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: March 24, 2015
    Assignee: University of Massachusetts
    Inventors: Neil Aronin, Edith Pfister, Phillip D. Zamore
  • Patent number: 8987435
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 24, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • Publication number: 20150080235
    Abstract: Described herein are compositions and methods for diagnosing or monitoring type 1 diabetes.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 19, 2015
    Inventor: Sahar Usmani-Brown
  • Publication number: 20150072345
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz
  • Publication number: 20150074836
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Application
    Filed: August 7, 2014
    Publication date: March 12, 2015
    Applicants: Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle
  • Patent number: 8975237
    Abstract: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: March 10, 2015
    Assignee: CoDa Therapeutics, Inc.
    Inventors: David L. Becker, Colin R. Green, Bradford James Duft
  • Publication number: 20150065378
    Abstract: Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, PCR primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: William Mathers, Zheng Ye
  • Publication number: 20150065380
    Abstract: The present invention relates to epilepsy-inducing brain somatic mutations which are associated with intractable epilepsy caused by malformations of cortical development, and uses thereof. More particularly, the present invention relates to an mTOR (Mammalian target of rapamycin) gene having mutations in a nucleotide sequence or an mTOR protein having mutations in an amino acid sequence resulting from the mutations in the nucleotide sequence. Further, the present invention relates to a technique for diagnosing intractable epilepsy caused by malformations of cortical development using the gene or the protein.
    Type: Application
    Filed: September 2, 2014
    Publication date: March 5, 2015
    Inventors: Jeong Ho LEE, Dong Seok Kim, Hoon Chul Kang, Jae Seok Lim, Woo-II Kim
  • Patent number: 8962582
    Abstract: The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR via RNA-HCR can be used to treat a wide variety of diseases and disorders by specifically targeting diseased cells.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: February 24, 2015
    Assignee: California Institute of Technology
    Inventors: Robert Dirks, Niles A. Pierce
  • Publication number: 20150051084
    Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Inventors: Attila Lorincz, Natasa Vasiljevic, Amar Ahmad
  • Publication number: 20150051103
    Abstract: Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 19, 2015
    Inventors: Cecilia Svanholm Barrie, Olivier Delfour, David H. Persing
  • Publication number: 20150045306
    Abstract: This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
    Type: Application
    Filed: August 25, 2014
    Publication date: February 12, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Amir Tchelet, Fabio Macciardi, Joseph Levy
  • Publication number: 20150045243
    Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of a disease in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of a disease in a body fluid sample from a subject.
    Type: Application
    Filed: October 5, 2012
    Publication date: February 12, 2015
    Inventors: Andreas Keller, Christina Backes, Markus Beier
  • Publication number: 20150044205
    Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Application
    Filed: August 11, 2014
    Publication date: February 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
  • Patent number: 8952145
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: February 10, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Publication number: 20150037251
    Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.
    Type: Application
    Filed: February 18, 2013
    Publication date: February 5, 2015
    Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
    Inventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
  • Patent number: 8945846
    Abstract: Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: February 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jason Robert Gotlib, Garry P. Nolan, James L. Zehnder, Stephen Tracy Oh
  • Publication number: 20150031749
    Abstract: A method of determining the Crohn's disease status of a subject comprising the steps of determining the level of miR-29 in a sample from said subject; and comparing the level of miR-29 determined in step (a) with one or more reference values.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 29, 2015
    Applicant: Isis Innovation Limited
    Inventor: Alison Simmons
  • Patent number: 8940479
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 27, 2015
    Assignee: Cornell University
    Inventors: Ann-Hwee Lee, Laurie H. Glimcher
  • Patent number: 8940504
    Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 27, 2015
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Thomas Dock Steenstrup, Peder Lisby Norby
  • Publication number: 20150024956
    Abstract: Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers.
    Type: Application
    Filed: November 19, 2012
    Publication date: January 22, 2015
    Inventors: Arsen Batagov, Anna Ivshina, Vladimir Kuznetsov
  • Patent number: 8936906
    Abstract: Disclosed is a means for improving the clinical outcomes of cancer therapy. Specifically disclosed is an activity potentiator comprising a compound capable of inhibiting the expression of RFP (RET finger protein) gene or the activity of RFP as an active ingredient. The activity of an anti-cancer agent having an oxidative stress inducing ability can be potentiated by using the anti-cancer agent in combination with the activity potentiator. Further specifically disclosed are a biomarker useful for the recognition of prognosis in a cancer patient and use of the biomarker.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 20, 2015
    Assignee: National University Corporation Nagoya University
    Inventors: Masahide Takahashi, Takuya Kato, Fumitaka Kikkawa
  • Publication number: 20150017637
    Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to gene fusions as diagnostic markers and clinical targets for cancer.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Arul Chinnaiyan, Yi-Mi Wu, Dan Robinson